Frederico Silva outlines the highlights of his two years heading up Gilead Sciences' relatively young Middle-East affiliate, how Gilead has pivoted to serve evolving healthcare needs during the COVID-19 pandemic, and its commitment to inter-stakeholder collaboration in increasingly important markets such as Saudi Arabia.
The Saudi FDA and other authorities are advancing in the protection of innovation, helping not only to create better access to innovation, but also encouraging more investment and reducing the barriers to expanding our footprint here. They can count on Gilead to be part of this growth story
